Objective To evaluate the clinical application value of amniotic membrane transplantation in the treatment of intrauterine adhesions.Methods Totally 48 intrauterine adhesions patients of infertility were treated with amniotic membrane transplantation from January to December 2013 in our hospital.They were divided into mild adhesion in 11 cases (group A),moderate adhesion in 17 cases (group B),and severe adhesive group in 20cases (group C) by American Fertility Association.They were treated with amniotic membrane transplantation and estrogen/progesterone sequential treatment after operation.Clinical effect and feasibility of each group were analyzed.Results There was statistical significance in the endometrium thickness after 3 months (P ＜ 0.05).The menstruation of all patients with mild and moderate intrauterine adhesion (IUA) was improved,and the menstrual improvement rate in patients with severe intrauterine adhesions was 90％.IUA cure rate of groups A,B,and C were different after 3 months of surgery,[groupA100％ (11/11),group B 94.1％ (16/17),group C70％ (14/20),x2 =6.73,P ＜0.01],The cure rate of group A was significantly higher than that of group C (x2 =4.00,P ＜ 0.05),although the cure rate of group B was higher than that of group A,but the difference was not statistically significant (P ＞ 0.05).Conclusions The cure rate of amniotic membrane transplantation combined with estrogen in the treatment of intrauterine adhesions was high.It could promote the recovery of the endometrium and improve the recovery of menstruation.There was no transplantation rejection and safety.It also had the advantages of easy drawing materials,simple operation,and can be applied to clinical application and promotion.

OBJECTIVE: To investigate the expression of high risk human papilloma virus (HPV) 16-E6 protein in non-neoplastic epithelial disorders of the vulva (NNEDV) and squamous cell carcinoma of the vulva (VSCC), and to explore whether HPV16-E6 protein is the etiological factor in NNEDV and its correlation with squamous cell carcinoma of the vulvae. METHODS: We detected HPV16-E6 protein expression in 15 normal vulvae cases, 40 NNEDV cases and 45 VSCC cases by immunohistochemistry SP method. RESULTS: The positive rate of HPV16-E6 in different vulva tissues: was 0% in the normal vulva, 30% in NNEDV and 66.67% in VSCC, respectively. The overall positive rate and two two comparison had statistical significance. In the NNEDV group, the positive rate of squamous hyperplasia type and lichen sclerosus type was 35% and 25%, respectively, with no statistical significance (P>0.05), but higher than that in the normal vulva skin group (P<0.05) and lower than that in the VSCC group (P<0.05). The positive rate of HPV16-E6 in VSCC was 66. 67%. The positive rate increased with the clinical stage. The positive rate between Phase I and Phase II, and that between Phase I and Phase III had statistical significance (P<0.017), but that between Phase II and Phase III had no statistical significance (P>0.017). The positive rate gradually decreased with the tumor differentiation. The difference in well-differentiated and poorly differentiated, moderately and poorly differentiated had statistical significance (P<0.017), but that of well-differentiated and moderately differentiated had no statistical significance (P>0.017). The positive rate of lymph node metastasis VSCC was significantly higher than that of non-lymph node metastasis VSCC (P<0.05). CONCLUSION HPV infection may be an etiological factor for NNEDV. The rise of HPV16-E6 positive rate may be related to the occurrence and development of vulvar squamous cell carcinoma.
Carcinoma, Squamous Cell ; metabolism ; virology ; Female ; Humans ; Hyperplasia ; Oncogene Proteins, Viral ; metabolism ; Papillomavirus Infections ; metabolism ; Precancerous Conditions ; metabolism ; virology ; Repressor Proteins ; metabolism ; Vulvar Diseases ; metabolism ; virology ; Vulvar Neoplasms ; metabolism ; virology